公开(公告)号：US20190337952A1

公开(公告)日：2019-11-07

申请号：US16462266

申请日：2017-11-20

Applicant: Novartis AG

Inventor： Hao Wang ,  Jiong Ye ,  Bo Han ,  Dietmar Flubacher ,  Hans Stettler ,  Fabrice Gallou ,  Franck Mallet ,  Matthias Napp ,  Michael Haller

IPC: C07D487/04

Abstract: The present disclosure relates to a method of synthesizing imidazopyrrolidi-none derivative, such as compound of formula (I), or a solvate including hydrate thereof, or a co-crystal thereof, and/or intermediates thereof, their use as pharmaceuticals and the use of intermediates.

公开(公告)号：US11414411B2

公开(公告)日：2022-08-16

申请号：US16635596

申请日：2018-08-01

Applicant: Novartis AG

Inventor： Like Chen ,  Chi Ming Cheung ,  Zhongbo Fei ,  Qun Jiang ,  Lei Li ,  Bin Li ,  Thomas Ruch ,  Hao Wang ,  Quanbing Wu

IPC: C07D417/14

Abstract: The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), or a salt thereof, or a solvate including hydrate thereof, and/or intermediates thereof, and the use of intermediates for preparing Compound X. In particular, the process relates to the preparation of Compound X using dynamic kinetic resolution (DKR) and asymmetric catalytic reduction, thereby providing an improved route to 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (Compound X) and compositions containing said compound, including the arginine salt, sodium salt and hydrated solid forms of Compound X.

公开(公告)号：US20210087194A1

公开(公告)日：2021-03-25

申请号：US17009215

申请日：2020-09-01

Applicant: Novartis AG

Inventor： Hao Wang ,  Jiong Ye ,  Bo Han ,  Dietmar Flubacher ,  Hans Stettler ,  Fabrice Gallou ,  Franck Mallet ,  Matthias Napp ,  Michael Haller

IPC: C07D487/04

Abstract: The present disclosure relates to a method of synthesizing imidazopyrrolidinone derivative, such as compound of formula (I), or a solvate including hydrate thereof, or a co-crystal thereof, and/or intermediates thereof, their use as pharmaceuticals and the use of intermediates.